MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
Zomedica Corp. Net Debt 2011-2026 | ZOM
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Zomedica Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.83 M | -5.21 M | -10.2 M | -25.7 M | -194 M | 466 K | -511 K | -1.94 M | -3.45 M | -82.1 K | -143 K | -207 K | -79.7 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 466 K | -194 M | -19 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Drug manufacturers industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aurora Cannabis
ACB
|
285 M | $ 3.45 | 0.58 % | $ 86.3 M |  Canada |
 |
Alimera Sciences
ALIM
|
-11.2 M | - | - | $ 142 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-22.5 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-11.1 M | - | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-6.59 M | - | 7.5 % | $ 6.35 M | USA |
 |
Canopy Growth Corporation
CGC
|
193 M | $ 1.02 | - | $ 110 M | Canada |
 |
Agile Therapeutics
AGRX
|
-676 K | - | 10.11 % | $ 58.2 M | USA |
 |
Cronos Group
CRON
|
-1.07 B | $ 2.54 | 1.6 % | $ 1.33 B | Canada |
 |
Assertio Holdings
ASRT
|
29.1 M | $ 11.77 | 1.99 % | $ 836 M | USA |
 |
DURECT Corporation
DRRX
|
-10.4 M | - | - | $ 50.1 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-49.7 M | - | - | $ 2.06 B |  France |
 |
Eagle Pharmaceuticals
EGRX
|
2.43 M | - | -39.89 % | $ 27.7 M | USA |
 |
Evolus
EOLS
|
94.8 M | $ 5.04 | 0.6 % | $ 325 M | USA |
 |
Evoke Pharma
EVOK
|
-2.96 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-931 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-150 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Catalent
CTLT
|
4.58 B | - | - | $ 11.5 B | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-12.7 M | $ 3.06 | 0.66 % | $ 43 M | USA |
 |
Jupiter Wellness
JUPW
|
-21.7 K | - | - | $ 33.6 M | USA |
 |
Athenex
ATNX
|
-28.3 M | - | -23.39 % | $ 1.76 M | USA |
 |
Endo International plc
ENDP
|
7.37 B | - | - | $ 28.9 M |  Irlanda |
 |
Harrow Health
HROW
|
178 M | $ 34.91 | 2.38 % | $ 1.28 B | USA |
 |
Emergent BioSolutions
EBS
|
338 M | $ 8.33 | 3.22 % | $ 426 M | USA |
 |
OrganiGram Holdings
OGI
|
90.7 M | $ 1.42 | 0.71 % | $ 402 M | Canada |
 |
China Pharma Holdings
CPHI
|
-4.73 M | $ 0.62 | 2.94 % | $ 10.8 M |  China |
 |
Sundial Growers
SNDL
|
-28.4 M | $ 1.44 | -4.64 % | $ 3.37 M | Canada |
 |
Organogenesis Holdings
ORGO
|
-131 M | $ 2.58 | -2.27 % | $ 340 M | USA |
 |
Pacira BioSciences
PCRX
|
317 M | $ 22.69 | -2.45 % | $ 1.05 B | USA |
 |
ProPhase Labs
PRPH
|
-6.41 M | - | - | $ 5.07 M | USA |
 |
Lannett Company
LCI
|
529 M | - | 1.15 % | $ 7.11 M | USA |
 |
Radius Health
RDUS
|
-111 M | - | - | $ 1.42 B | USA |
 |
Perrigo Company plc
PRGO
|
3.1 B | $ 9.72 | 4.4 % | $ 1.35 B | USA |
 |
Neoleukin Therapeutics
NLTX
|
-146 M | - | - | $ 193 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-5.29 M | $ 2.4 | -2.24 % | $ 2.98 M | USA |
 |
Relmada Therapeutics
RLMD
|
-2.5 M | $ 6.18 | 4.57 % | $ 186 M | USA |
 |
Rockwell Medical
RMTI
|
691 K | $ 0.96 | 6.61 % | $ 22.4 M | USA |
 |
PetIQ
PETQ
|
329 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
-72.2 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-21.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
SCYNEXIS
SCYX
|
-19.1 M | $ 0.9 | 4.68 % | $ 44.9 M | USA |
 |
Recro Pharma
REPH
|
-6.65 M | - | -4.76 % | $ 65.3 M | USA |
 |
TherapeuticsMD
TXMD
|
3.68 M | $ 2.17 | - | $ 22.7 M | USA |
 |
Solid Biosciences
SLDB
|
-70.9 M | $ 7.48 | 2.33 % | $ 305 M | USA |
 |
Veru
VERU
|
-20.9 M | $ 2.37 | -0.84 % | $ 320 M | USA |
 |
Tilray
TLRY
|
14.4 M | $ 6.9 | 0.15 % | $ 4.26 B | Canada |
 |
Viatris
VTRS
|
16.8 B | $ 13.51 | - | $ 16.2 B | USA |
 |
Tricida
TCDA
|
-7.08 M | - | - | $ 3.25 M | USA |
 |
cbdMD
YCBD
|
-521 K | $ 0.72 | 1.41 % | $ 3.11 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-50.3 M | - | - | $ 55.5 M | USA |